doi : 10.1016/S1936-8798(22)02298-1
Volume 16, Issue 2, 23 January 2023, Pages A1-A4
Antonio Sisinni, MD, a,b Maurizio Taramasso, MD, c Fabien Praz, MD,d Marco Metra, MD, e Eustachio Agricola, MD, f Alberto Margonato, MD,g Neil Fam, MD,h Rodrigo Estevez-Loureiro, MD,i Azeem Latib, MD,j David Messika-Zeitoun, MD, k Lenard Conradi, MD,l Ralph Stephan von Bardeleben, MD,m Paul Sorajja, MD, n Rebecca T. Hahn, MD,o Sergio Caravita, MD,p,q Francesco Maisano, MD,g Marianna Adamo, MD, r Cosmo Godino, MD
doi : 10.1016/j.jcin.2022.11.022
Volume 16, Issue 2, 23 January 2023, Pages 127-139
Secondary (functional) tricuspid regurgitation (sTR) is common in patients with mitral regurgitation (MR).
Lukas Stolz, MD, a Philipp M. Doldi, MD,a,b Mathias Orban, MD, b Nicole Karam, MD, c Tania Puscas, MD, c Mirjam G. Wild, MD,a Aniela Popescu, MD,d Ralph Stephan von Bardeleben, MD,d Christos Iliadis, MD,e Stephan Baldus, MD,e Marianna Adamo, MD,f Holger Thiele, MD,g Christian Besler, MD, f Matthias Unterhuber, MD, f Tobias Ruf, MD,d Roman Pfister, MD,e Satoshi Higuchi, MD, a Benedikt Koell, MD, h,i Christina Giannini, MD,j Anna Petronio, MD,j Mohammad Kassar, MD,k Ludwig T. Weckbach, MD,a,b Christian Butter, MD, l Thomas J. Stocker, MD,a,b Michael Neuss, MD, l Bruno Melica, MD,m Daniel Braun, MD,a Stephan Windecker, MD, k Steffen Massberg, MD, a,b Fabien Praz, MD,k Micheal Näbauer, MD,a Daniel Kalbacher, MD, h,i Philipp Lurz, MD,g Marco Metra, MD, f Jeroen J. Bax, MD, n,o Jörg Hausleiter, MD,a,b on behalf of the EuroSMR Investigators
doi : 10.1016/j.jcin.2022.10.032
Volume 16, Issue 2, 23 January 2023, Pages 140-151
Secondary mitral regurgitation (SMR) is a progressive disease with characteristic pathophysiological changes that may influence prognosis. Although the staging of SMR patients suffering from heart failure with reduced ejection fraction (HFrEF) according to extramitral cardiac involvement has prognostic value in medically treated patients, such data are so far lacking for edge-to-edge mitral valve repair (M-TEER).
Philippe Généreux, MD
doi : 10.1016/j.jcin.2022.11.004
Volume 16, Issue 2, 23 January 2023, Pages 152-155
Vidhu Anand, MBBS, a Christopher G. Scott, MS, b Meredith C. Hyun,b Kyla Lara-Breitinger, MD, a Vuyisile T. Nkomo, MD, MPH,a Garvan C. Kane, MD, PHD, a Cristina Pislaru, MD, a Kathleen F. Kopecky, MD, a Phillip J. Schulte, PH D, c Sorin V. Pislaru, MD, PHD
doi : 10.1016/j.jcin.2022.10.055
Volume 16, Issue 2, 23 January 2023, Pages 156-165
The recent morphologic classification of tricuspid regurgitation (TR) (ie, atrial functional, ventricular functional, lead related, and primary) does not capture underlying comorbidities and clinical characteristics.
Jörg Hausleiter, MD,a,b Nicole Karam, MD, PH D
doi : 10.1016/j.jcin.2022.11.023
Volume 16, Issue 2, 23 January 2023, Pages 166-167
P. Michael Grossman, MD,a Devraj Sukul, MD, MS C,a Shelly C. Lall, MD,b Pedro A. Villablanca, MD, c Francis Shannon, MD,d Milan Seth, MS, a Stanley J. Chetcuti, MD, a Himanshu J. Patel, MD,a G. Michael Deeb, MD
doi : 10.1016/j.jcin.2022.10.020
Volume 16, Issue 2, 23 January 2023, Pages 168-176
The 30-day rate of stroke after transcatheter aortic valve replacement (TAVR) has been suggested as a hospital quality metric. Thirty-day stroke rates for nonsurgical, high, and moderate-risk TAVR trials were 3.4% to 6.1%, whereas those in the national Transcatheter Valve Therapy (TVT) Registry for the same patient population were much lower.
Alexandra J. Lansky, MD, Yousif Ahmad, PHD
doi : 10.1016/j.jcin.2022.11.010
Volume 16, Issue 2, 23 January 2023, Pages 177-178
Jarl E. Strange, MD,a,b Caroline Sindet-Pedersen, MSC , P HD, b,c Anders Holt, MD,b Mikkel P. Andersen, MSC PH, PH D, d Christian Torp-Pedersen, MD, DMSC ,d Lars Køber, MD, DMS C, a Gunnar H. Gislason, MD, PHD, b,c,e Jonas B. Olesen, MD, PH D, b Emil L. Fosbøl, MD, P HD
doi : 10.1016/j.jcin.2022.10.051
Volume 16, Issue 2, 23 January 2023, Pages 179-188
Loss of autonomy associated with nursing home admission (NHA) is a concern for patients. Yet the incidence of NHA after transcatheter aortic valve replacement (TAVR) is unknown.
Abdulla A. Damluji, MD, PH D, a,b Jennifer A. Rymer, MD, MHS,c Michael G. Nanna, MD, MHS
doi : 10.1016/j.jcin.2022.12.008
Volume 16, Issue 2, 23 January 2023, Pages 189-192
Antonio Landi, MD,a Mattia Branca, P HD, b Sergio Leonardi, MD, MHS, c Enrico Frigoli, MD,a,b Pascal Vranckx, MD, PHD, d,e Matteo Tebaldi, MD,f Ferdinando Varbella, MD, g,h Paolo Calabró, MD, P HD, i,j Giovanni Esposito, MD, PH D, k Gennaro Sardella, MD,l Stefano Garducci, MD,m Giuseppe Andò, MD, PHD, n Ugo Limbruno, MD,o Paolo Sganzerla, MD, p Andrea Santarelli, MD, q Carlo Briguori, MD, P HD, r Salvatore Colangelo, MD, s Salvatore Brugaletta, MD, P HD, t Marianna Adamo, MD, u Elmir Omerovic, MD, PHD, v,w Dik Heg, PH D, b Stephan Windecker, MD, x Marco Valgimigli, MD, PH D, a,y on behalf of the MATRIX Investigators
doi : 10.1016/j.jcin.2022.10.009
Volume 16, Issue 2, 23 January 2023, Pages 193-205
The occurrence of acute kidney injury (AKI) among patients with acute coronary syndrome (ACS) undergoing invasive management is associated with worse outcomes. However, the prognostic implications of transient or in-hospital persistent AKI may differ.
Robert N. Piana, MD, Alexander E. Sullivan, MD
doi : 10.1016/j.jcin.2022.10.052
Volume 16, Issue 2, 23 January 2023, Pages 206-208
Mandeep S. Sidhu, MD, a Karen P. Alexander, MD, b Zhen Huang, MS, b Roy O. Mathew, MD, c Jonathan D. Newman, MD, MPH, d Sean M. O’Brien, PHD, b Patricia A. Pellikka, MD, e Radmila Lyubarova, MD, a Olga Bockeria, MD, PHD, f Carlo Briguori, MD, P HD, g Evgeny L. Kretov, MD, h Tomasz Mazurek, MD, P HD, i Francesco Orso, MD,j Marek F. Roik, MD, P HD, k Chakkanalil Sajeev, MD, l Evgeny V. Shutov, DM,m Frank W. Rockhold, SC M, P HD, b David Borrego, PH D, n Stephen Balter, PH D, o Gregg W. Stone, MD,p Bernard R. Chaitman, MD,q Shaun G. Goodman, MD, MS C,r Jerome L. Fleg, MD,s Harmony R. Reynolds, MD,d David J. Maron, MD,t Judith S. Hochman, MD,d Sripal Bangalore, MD, MHA, d on behalf of the ISCHEMIA-CKD Research Group
doi : 10.1016/j.jcin.2022.10.062
Volume 16, Issue 2, 23 January 2023, Pages 209-218
In ISCHEMIA-CKD, 777 patients with advanced chronic kidney disease and chronic coronary disease had similar all-cause mortality with either an initial invasive or conservative strategy (27.2% vs 27.8%, respectively).
Hitinder S. Gurm, MD, George Hanna, MD
doi : 10.1016/j.jcin.2022.12.001
Volume 16, Issue 2, 23 January 2023, Pages 219-221
Fabian Barbieri, MD, PH D, a Sebastian Biewener, MD, a Mario Kasner, MD, a Markus Reinthaler, MD, a,b Patrick Nagel, MD
doi : 10.1016/j.jcin.2022.10.007
Volume 16, Issue 2, 23 January 2023, Pages 222-225
Ivan Wong, MBBS, Michael Chiang, MBBS, Angus Shing Fung Chui, MBCHB, Alan Ka Chun Chan, MBBS, Kam Tim Chan, MBBS, Michael Kang-Yin Lee, MBBS
doi : 10.1016/j.jcin.2022.10.039
Volume 16, Issue 2, 23 January 2023, Pages 226-228
Bassel Mohammad Nijres, MD, Benjamin Reinking, MD, Osamah Aldoss, MD
doi : 10.1016/j.jcin.2022.10.022
Volume 16, Issue 2, 23 January 2023, Pages 229-230
Mi Chen, MD, P HD, a Jonathan M. Michel, MD,a Martin Oliver Schmiady, MD, b Barbara E. Stähli, MD, a Thomas S. Gilhofer, MD, a Felix C. Tanner, MD,a Albert Markus Kasel, MD
doi : 10.1016/j.jcin.2022.10.060
Volume 16, Issue 2, 23 January 2023, Pages 231-234
Ignacio Sánchez-Pérez, MD, a Ricardo Concepción-Suárez, MD,a Fernando Lozano-RuÃz-Poveda, MD, PH D, a Maria Thiscal López-Lluva, MD, P HD, b Ariana Gonzálvez-GarcÃa, MD, a Alfonso Freites-Esteves, MD, a Jose MarÃa Hernández-GarcÃa, MD, PHD
doi : 10.1016/j.jcin.2022.10.040
Volume 16, Issue 2, 23 January 2023, Pages 235-236
Filippo Zilio, MD Antonio La Torre, MD Giuseppe Ciliberti, MD, PhD Federico Fortuni, MD, PhD Roberto Bonmassari, MD
doi : 10.1016/j.jcin.2022.11.015
Volume 16, Issue 2, 23 January 2023, Page 237
Cameron McAlister, MD *Jacqueline Saw, MD
doi : 10.1016/j.jcin.2022.12.002
Volume 16, Issue 2, 23 January 2023, Pages 237-238
Anastasios Apostolos, MD Georgios Vasilagkos, MD *Grigorios Tsigkas, MD, PhD
doi : 10.1016/j.jcin.2022.12.003
Volume 16, Issue 2, 23 January 2023, Pages 238-239
Giuseppe Ferrante, MD, PhD Sunil V. Rao, MD Marco Valgimigli, MD, PhD
doi : 10.1016/j.jcin.2022.12.011
Volume 16, Issue 2, 23 January 2023, Pages 239-240
Alexandre Silini, MD Patrice Guerin, MD, PhD Zakaria Jalal, MD, PhD Lionel Leroux, MD, PhD Robin Le Ruz, MD Laurianne Le Gloan, MD Charlène Bredy, MD Helene Bouvaist, MD, PhD Jean-Benoit Thambo, MD, PhD *Xavier Iriart, MD
doi : 10.1016/j.jcin.2022.09.051
Volume 16, Issue 2, 23 January 2023, Pages 240-242
Lukas Stolz, MD Philipp M. Doldi, MD Ludwig T. Weckbach, MD Felicitas Trimborn, Cand Med Mathias Orban, MD Thomas J. Stocker, MD Mirjam G. Wild, MD Steffen Massberg, MD Michael Näbauer, MD *Jörg Hausleiter, MD
doi : 10.1016/j.jcin.2022.09.034
Volume 16, Issue 2, 23 January 2023, Pages 242-244
Haim D. Danenberg, MD Yan Topilsky, MD David Planer, MD Elad Maor, MD Victor Guetta, MD Horst Sievert, MD Jörg Hausleiter, MD Chani Carmel, RDCS Kerstin Piayda, MD Nir Flint, MD Dana Yaron, BSc Ronen Beeri, MD
doi : 10.1016/j.jcin.2022.09.035
Volume 16, Issue 2, 23 January 2023, Pages 244-246
doi : 10.1016/S1936-8798(22)02328-7
Volume 16, Issue 2, 23 January 2023, Pages I-CXXIV
Do you want to add Medilib to your home screen?